<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457661</url>
  </required_header>
  <id_info>
    <org_study_id>20-036-A</org_study_id>
    <nct_id>NCT04457661</nct_id>
  </id_info>
  <brief_title>Evaluation of the Alcohol Elimination Effect of TCI711 Probiotic (Bacillus Coagulans) on Adult Individuals</brief_title>
  <acronym>TCI711</acronym>
  <official_title>Evaluation of the Alcohol Elimination Effect of TCI711 Probiotic (Bacillus Coagulans) on Adult Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TCI Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GeNext</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TCI Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the possibility of using Bacillus coagulans TCI711 to improve the efficiency of
      alcohol removal in adult individuals.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 13, 2020</start_date>
  <completion_date type="Anticipated">June 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Breath Alcohol Level</measure>
    <time_frame>5 minutes after drinking a certain volume of whisky</time_frame>
    <description>A breathalyzer will be used for estimating blood alcohol content (BAC) from a breath sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Alcohol Level</measure>
    <time_frame>15 minutes after drinking a certain volume of whisky</time_frame>
    <description>A breathalyzer will be used for estimating blood alcohol content (BAC) from a breath sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Alcohol Level</measure>
    <time_frame>30 minutes after drinking a certain volume of whisky</time_frame>
    <description>A breathalyzer will be used for estimating blood alcohol content (BAC) from a breath sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Alcohol Level</measure>
    <time_frame>60 minutes after drinking a certain volume of whisky</time_frame>
    <description>A breathalyzer will be used for estimating blood alcohol content (BAC) from a breath sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Alcohol Level</measure>
    <time_frame>90 minutes after drinking a certain volume of whisky</time_frame>
    <description>A breathalyzer will be used for estimating blood alcohol content (BAC) from a breath sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Alcohol Level</measure>
    <time_frame>120 minutes after drinking a certain volume of whisky</time_frame>
    <description>A breathalyzer will be used for estimating blood alcohol content (BAC) from a breath sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Alcohol Level</measure>
    <time_frame>150 minutes after drinking a certain volume of whisky</time_frame>
    <description>A breathalyzer will be used for estimating blood alcohol content (BAC) from a breath sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Alcohol Level</measure>
    <time_frame>180 minutes after drinking a certain volume of whisky</time_frame>
    <description>A breathalyzer will be used for estimating blood alcohol content (BAC) from a breath sample.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breath Alcohol Level</condition>
  <arm_group>
    <arm_group_label>TCI711 probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taking one capsule (containing 10^10 of Bacillus coagulans TCI711) daily for one month</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bacillus coagulans TCI711</intervention_name>
    <description>Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.</description>
    <arm_group_label>TCI711 probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers aged between 20 to 60.

          -  Systolic pressure below 140

          -  Score of C-CAGE Questionnaire below 8 (male)/6 (female)

          -  Prohibiting other supplements before 2 weeks of the study and during the study

          -  Prohibiting alcohol drinks before 24 hours of the study

          -  Prohibiting caffeine drinks before 12 hours of the study

        Exclusion Criteria:

          -  Alcohol or drug allergy

          -  Liver, kidney, cardiovascular, or chronic diseases

          -  Other severe disorders

          -  Hypertension

          -  Pregnancy or lactation

          -  Already involved in clinical testing

          -  Other supplements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>GeNext</name>
      <address>
        <city>Taipei City</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Kang-Liang Chen, MD</last_name>
      <phone>886-972-758-123</phone>
      <email>ahlchan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kang-Liang Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

